STEP trial and HIV-1 vaccines inducing T-cell responses.
Recombinant, nonreplicating, human adenovirus serotype 5-vectored vaccine, known as MRKAd5, expressing three HIV-1 clade B-derived internal proteins when used in a homologous immunization regimen, did not decrease HIV-1 infection rate nor postinfection virus load in the first Phase IIb proof-of-concept trial. However, the vaccine did not reach the limits of vaccine T-cell induction and its design can be improved both from the point of the HIV-1-derived immunogens and their delivery. Therefore, failure of the first experimental HIV-1 vaccine focusing on induction of T-cell responses cannot be a reason for dismissal of the whole T-cell vaccine concept, nor for losing a positive attitude toward systematic HIV-1 vaccine development.
Hanke
Tomás
T
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, The John Radcliffe, Oxford OX3 9DS, UK. tomas.hanke@imm.ox.ac.uk
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology* / Q000821:virology*; D017211:Treatment Failure; D019562:Viral Load / Q000379:methods
D016915:AIDS Vaccines